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TO THE EDITOR
Colchicine (COL) is a microtubule
depolymerizing drug that has been
widely used for the treatment of many
inflammatory skin diseases, such as
Behc¸et disease, psoriasis, palmoplantar
pustulosis, Sweet’s syndrome, and leu-
kocytoclastic vasculitis (Sullivan et al.,
1998; Bibas et al., 2005). With regard
to its pharmacological mechanisms of
action, COL is thought to primarily
inhibit various functions of polymor-
phonuclear neutrophils, including
mitosis, adhesion, migration, and pha-
gocytosis (Keller et al., 1984; Cronstein
et al., 1995; Blocker et al., 1997; Jordan
and Wilson, 2004). We recently re-
ported totally unexpected pharmacolo-
gical activities of COL (Mizumoto et al.,
2005). Briefly, COL at relatively low
concentrations triggered phenotypic
maturation of murine bone marrow
(BM)-derived dendritic cells (DCs) as
well as their production of several
cytokines and chemokines. Moreover,
BM-DCs pretreated with COL exhibited
enhanced capacities to activate allo-
geneic T cells and to present a foreign
protein antigen to immunologically
naive CD4 T cells. Interestingly, COL
pretreatment markedly improved the
ability of BM-DCs to uptake FITC-
conjugated dextran (DX). Upon local
injection in low doses, COL promoted
in situ maturation and mobilization
of epidermal Langerhans cells and
boosted both humoral and cellular
immune responses in mice (Mizumoto
et al., 2005). These observations may
appear to be rather contradictory to the
conventional view that COL acts as an
anti-inflammatory agent (when admi-
nistered systemically at high doses).
Thus, we first sought to study in vitro
effects of COL on human DCs.
For this purpose, we employed hu-
man DC preparations generated from
CD34þ progenitors in the cord blood.
Following 24-hour pretreatment with
3 mg/ml COL, we examined surface
expression of major histocompatibility
complex (MHC) class II molecules,
CD83, and co-stimulatory molecules
CD40, CD80, and CD86 within the
CD1aþ populations. COL treatment
significantly elevated the expression of
all tested markers of DC maturation
without affecting their viability (Figure 1a).
Abbreviations: BM, bone marrow; COL, colchicine; DC, dendritic cell; DX, dextran; ER, endoplasmic
reticulum; MHC, major histocompatibility complex; OVA, ovalbumin; TAP, transporter associated with
antigen presentation
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Moreover, COL triggered robust pro-
duction of IL-6, IL-8, macrophage in-
flammatory protein-1a, macrophage
inflammatory protein-3a, and regulated
on activation, normal T cell expressed
and secreted chemokine (Figure 1b).
However, COL failed to induce signifi-
cant production of tumor necrosis
factor-a. Importantly, COL pretreatment
also improved the ability of human DCs
to uptake FITC-DX as observed with
murine DCs. Control human DCs trea-
ted with vehicle alone showed modest
FITC-DX uptake at 371C and minimal
surface binding at 41C, whereas COL-
treated DCs showed an augmented
endocytic capacity (Figure 1c). Quanti-
tative analysis revealed 5-fold im-
provement of FITC-DX uptake after
COL treatment (Figure 1d). Heteroge-
neity of the FITC-DX uptake profile
observed in COL-treated human DC
populations did not appear to reflect
their states of maturation because CD86
expression was elevated uniformly in
an overwhelming majority of such
populations after COL treatment (data
not shown).
COL treatment of murine BM-DCs
augmented their capacity to internalize
not only FITC-DX, but also FITC-BSA
(Figure 2a). These observations may first
appear to be contradictory to the
general notion that DCs downregulate
their endocytic capacity upon matura-
tion (Sallusto et al., 1995). Selected
Toll-like receptor ligands, including
lipopolysaccharides, have been re-
ported to enhance DC endocytosis via
causing rapid reorganization of actin
cytoskeletal filaments (West et al.,
2004). When compared with COL in
parallel, however, lipopolysaccharides
induced only marginal, if any, augmen-
tation of the uptake of FITC-DX or FITC-
BSA by BM-DCs (data not shown). Our
findings with COL now suggest that
endocytic machinery may be regulated
by the extent of microtubule polymer-
ization in DCs. Indeed, confocal micro-
scopic study revealed partial disruption
of microtubule networks in COL-treated
BM-DCs, whereas control DCs treated
with vehicle alone showed well-deve-
loped microtubule formation (Figure
2b). No significant change was ob-
served in the actin microstructures after
COL treatment.
Upon incorporation of apoptotic
bodies and cellular proteins derived
from virally infected cells and dying
tumor cells, DCs are known to present
the MHC II and MHC I peptide epitopes
to CD4 and CD8 T cells, respectively
(Huang et al., 1994; Albert et al., 1998;
Sigal et al., 1999). The latter event,
termed ‘‘cross-presentation,’’ represents
an unusual antigen processing pathway
in which exogenous antigens are pre-
sented in a MHC I-restricted manner to
CD8 T cells (Ackerman and Cresswell,
2004). With regard to mechanisms,
cross-presentation involves the fusion
of endoplasmic reticulum (ER) with
early phagosomes to form specialized
organelles equipped with all the com-
ponents required for MHC I peptide
loading, such as newly synthesized
MHC I molecule, transporter associated
with antigen presentation (TAP), tapa-
sin, and calreticulin. After ER–phago-
some formation, maturation of
ER–phagosomes through the endocytic
pathway results in acquisition of lyso-
somal components that help the break-
down of internalized proteins. These
polypeptides then are retro-transported
to the cytosol for proteasome-depen-
dent degradation, and the resulting
peptides are transported back to the
phagosomes via TAP complex for MHC
I loading (Ackerman and Cresswell,
2004; Heath et al., 2004; Trombetta
and Mellman, 2005). Thus, we next
examined the subcellular localization
of exogenous antigens endocytosed by
COL-stimulated DCs using FITC-DX as
a probe. FITC fluorescent signals
showed almost complete overlap with
the blue fluorescent signals demarcat-
ing the ER compartments within
10 minutes of incubation (Figure 2c).
Moreover, colocalization of FITC fluor-
escent signals with the red fluorescent
signals demarcating the lysosomal com-
partments became detectable 30-min-
utes post-internalization (Figure 2d).
We interpret these patterns to suggest
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Figure 1. In vitro impacts of COL on human DCs. (a) Human DC cultures generated from CD34þ
progenitors purified from the cord blood were purchased from MatTek Corporation (Ashland, MA); an
overwhelming majority of these DCs reportedly expresses CD1a, a marker of human Langerhans cells.
Following 24-hour incubation with 3 mg/ml COL or vehicle alone, human DCs were examined for the
surface expression of the indicated markers within the CD1aþ populations and for cell viability by
propidium iodide uptake (mean7SD, n¼ 3). (b) The supernatants of the same human DC cultures were
examined for the secretion of the indicated cytokines and chemokines (mean7SD, n¼3). (c) Following
24-hour incubation with 3 mg/ml COL or vehicle alone, human DCs were examined for their capacity to
uptake FITC-DX (70,000 Da molecular weight) from Sigma (St Louis, MO) at 41C (broken lines) or 371C
(solid lines). The data shown are representative histograms for the FITC fluorescent signals within the
CD1aþ populations. (d) The data shown are the mean7SD (n¼ 3) of the mean fluorescence intensity
(MFI) of FITC-DX uptake of COL-treated or vehicle-treated human DCs tested at 41C (open bars) or 371C
(closed bars). Statistically significant differences compared with the vehicle-treated control samples are
indicated with asterisks (*Po 0.05, **Po 0.01). Each experiment was repeated at least three times to
assess reproducibility.
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sequential intracellular transports of the
internalized probe to the phagosom-
e–ER fusion compartments and then to
the lysosome, a major antigen proces-
sing pathway for cross-presentation
(Trombetta and Mellman, 2005).
The above observations implied
further that COL may promote cross-
presentation of exogenous antigens to
CD8 T cells. In fact, COL-treated BM-
DCs exhibited marked (5-fold) and
significant (Po0.01) improvement over
the vehicle-treated control DCs in their
ability to cross-present intact ovalbu-
min (OVA) proteins (300mg/ml) to CD8
T cells freshly isolated from OT-I TCR
transgenic mice, in which a majority of
CD8 T cells recognize the OVA257–264
peptide (SIINFEKL) presented by the
MHC I molecules, H-2Kb (Figure 2e).
By contract, COL treatment induced
only marginal (up to 1.2-fold) improve-
ment in their ability to present the
OVA257–264 peptide (10 mg/ml) to the
same OT-I CD8 T ceils. It should be
noted that the extent of T-cell growth
induced by COL-treated/OVA protein-
loaded DCs (i.e., up to 65,000 c.p.m.)
was substantial when compared to the
extent observed in our positive control
in which COL-treated DCs were pulsed
with excessive amounts of the
OVA257–264 peptide (i.e., up to 170,000
c.p.m.). In antigen dose-dependency
experiments, COL-treated DCs were
found to be much more efficient than
vehicle-treated DCs in their capacity to
cross-present (10–100mg/ml) OVA pro-
teins to OT-I T cells at all tested antigen
concentrations (Figure 2f). Once again,
COL treatment induced no significant
or only marginal improvement of their
capacity to present the OVA257–264
peptide even in a lower concentration
range (1–3 mg/ml). Taken together, these
observations demonstrate that COL en-
hances the in vitro ability of murine
BM-DCs to cross-present a protein
antigen to CD8 T cells.
To recapitulate the essence of our
new observations, COL was found to
promote phenotypic maturation and
cytokine/chemokine production by hu-
man DCs. We also found that COL
markedly augments the ability of mur-
ine BM-DCs to cross-present exogenous
protein antigens to CD8 T cells. At least
two key questions, however, remain to
be addressed experimentally. Does
COL treatment also enhance antigen
cross-presentation by human DCs? Can
we use COL (or COL-pretreated DCs) to
promote cross-presentation of tumor-
associated antigens or microbial
antigens in vivo? Nevertheless, this
study suggests a previously unrecog-
nized pharmacological activity of
COL, which should be taken into
consideration when administering
COL to patients with inflammatory skin
disorders.
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Figure 2. Enhanced antigen cross-presenting capacity by COL-treated murine DCs. (a) Following
24-hour incubation with 3 mg/ml COL or vehicle alone, BM-DCs propagated from BALB/c mice were
examined for their capacity to uptake FITC-DX, or FITC-BSA at 41C (open bars), or 371C (closed bars).
Samples then were examined for FITC signals (mean7SD, n¼ 3) within the CD11cþ populations.
(b) After 24-hour incubation with 3 mg/ml COL or vehicle alone, BM-DCs were stained for tubulin (green)
or actin (red), and then examined by confocal microscopy (Leica Microsystems, Wetzlar, Germany).
Fluorescence was detected using a 100/1.4 numeric aperture apochromatic objective (APO). Images
shown are maximum intensity projections of the x–y planes generated by MetaMorph software (Universal
Imaging, Downingtown, PA) and ImageJ program (NIH, Bethesda, MD). Bar¼ 25mm. (c) Following
24-hour pretreatment with 3 mg/ml COL, BM-DCs were stained with ER-Tracker Blue-White DPX dye
(blue) from Molecular Probes (Eugene, OR) and then incubated with FITC-DX (green). (d) The same BM-
DC cultures were allowed to internalize FITC-DX first, extensively washed, and then stained for lysosome
(red) with LysoTracker Red DND-99 (Molecular Probes) for an additional 30 minutes at 371C to allow
complete transfer of DX to the lysosome. Colocalization of FITC-DX with ER or lysosome was examined
by confocal microscopy. All two-color images were acquired with a sequential scan mode using Leica
Confocal Software. Bar¼ 25 mm. (e) Following 24-hour pretreatment with 3 mg/ml COL (open symbols) or
vehicle alone (closed symbols), BM-DCs propagated from C57BL/6 mice were pulsed for 1 hour with
300mg/ml OVA protein (left panel), 10mg/ml OVA257–264 peptide (circles in right panel), or PBS alone
(triangles). After extensive washing, the DC samples were co-cultured at the indicated numbers with
OVA-reactive CD8T cells (5104 cells/well) purified from OT-I transgenic mice (kindly provided by Dr
James Foreman, UT Southwestern). Data shown are 3H-thymidine uptake on day 4 (mean7SD, n¼3).
(f) The above experiments were repeated by pulsing COL-treated DCs (open circles) or vehicle-treated
DCs (closed circles) with OVA protein (left panel) or OVA257–264 peptide (right panel) at the indicated
antigen concentrations. After extensive washing, the DC samples (103 cells/well) were co-cultured with
OVA-reactive CD8 T cells (5104 cells/well) to measure 3H-thymidine uptake on day 4. Statistically
significant differences compared with the vehicle-treated DCs are indicated with asterisks (*Po0.05,
**Po0.01).
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TO THE EDITOR
Photodynamic therapy (PDT) is based
on the concept that a certain photo-
activatable compound, called a photo-
sensitizer, can be excited by light of the
appropriate wavelength to generate
cytotoxic singlet oxygen and free radi-
cals (Hasan et al., 2006). Although
earlier reports of PDT involved micro-
biological applications (Raab, 1900),
clinically PDT has been developed
most extensively for oncologic and
ophthalmologic applications. Recent
clinical outcomes of PDT using
d-aminolevulinic acid (ALA)-induced
protoporphyrin IX (PpIX), termed
ALA-PDT, in patients with cutaneous
leishmaniasis (CL) have been promising
(Enk et al., 2003; Gardlo et al., 2003,
2004; Asilian and Davami, 2006), but
far from being curative.
ALA by itself is not a photosensitizer,
but is processed to PpIX in the heme
biosynthetic pathway where it serves as
a biological precursor of PpIX. It is
known that Leishmania amazonensis
parasites are deficient in seven out of
eight enzymes in the heme biosynthetic
pathway (Sah et al., 2002). Although
Leishmania major (L. major) have not
been studied for this enzyme defi-
ciency, as they require extracorporeal
supplementation with PpIX or hemin as
a growth factor in vitro (Steiger and
Steiger, 1976; Chang and Chang,
1985), it is reasonable to assume that
they may also be deficient in these
enzymes, and that they cannot produce
PpIX from ALA. Therefore, the reported
efficacy of ALA-PDT for CL is some-
what intriguing.
Encouraged by clinical reports, and
with a view to increasing the efficacy of
ALA-PDT for CL, we performed a series
of in vitro and in vivo experiments to
unravel the underlying mechanisms
associated with this clinical response.
In an attempt to better understand the
basis of ALA-PDT for CL, we identified
several key questions that are addressed
here: first of all, how does ALA-PDT
work for CL? At the cellular level, is
ALA-PpIX produced by Leishmania or
by host cells, or by both? Do Leishma-
nia parasites take up ALA-PpIX from
host cells?
We studied a series of cellular
events in Leishmania parasites and in
infected immortalized macrophages
(J774.2) during ALA-PDT. The amount
of PpIX in the stationary phase of a
Abbreviations: ALA, d-aminolevulinic acid; ALA-PDT, photodynamic therapy with 5-aminolevulinic
acid-induced protoporphyrin IX; ALA-PpIX, 5-aminolevulinic acid-induced protoporphyrin IX
CL, cutaneous leishmaniasis; PDT, photodynamic therapy; PpIX, protoporphyrin IX
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